WiseGuy Report’s latest Pharmaceutical and Healthcare disease pipeline guide Retinal Vein Occlusion – Pipeline Review, H2 2016, provides an overview of the Retinal Vein Occlusion (Ophthalmology) pipeline landscape.
Retinal vein occlusion is a blockage in one of the veins returning blood flow from the retina. The retina is where images are converted to nerve signals. The primary symptom of retinal vein occlusion is a sudden painless change in vision. Predisposing factors are atherosclerosis, macular edema, diabetes, high blood pressure, high cholesterol and age.
WiseGuy Report’s Pharmaceutical and Healthcare latest pipeline guide Retinal Vein Occlusion – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Retinal Vein Occlusion (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Retinal Vein Occlusion (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinal Vein Occlusion and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 4, 7 and 1 respectively. Retinal Vein Occlusion.
Retinal Vein Occlusion (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from WiseGuy Report’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Retinal Vein Occlusion (Ophthalmology).
– The pipeline guide reviews pipeline therapeutics for Retinal Vein Occlusion (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Retinal Vein Occlusion (Ophthalmology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Retinal Vein Occlusion (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Retinal Vein Occlusion (Ophthalmology)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Retinal Vein Occlusion (Ophthalmology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Retinal Vein Occlusion (Ophthalmology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Content
Table of Contents 2
List of Tables 5
List of Figures 5
Global Markets Direct Report Coverage 6
Retinal Vein Occlusion Overview 7
Therapeutics Development 8
Pipeline Products for Retinal Vein Occlusion – Overview 8
Retinal Vein Occlusion – Therapeutics under Development by Companies 9
Retinal Vein Occlusion – Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Retinal Vein Occlusion – Products under Development by Companies 13
Retinal Vein Occlusion – Companies Involved in Therapeutics Development 14
Aerpio Therapeutics, Inc. 14
Clearside BioMedical, Inc. 15
Formycon AG 16
Kala Pharmaceuticals, Inc. 17
Mabion SA 18
NicOx S.A. 19
Ohr Pharmaceutical Inc. 20
Precision Ocular Ltd 21
ThromboGenics NV 22
Retinal Vein Occlusion – Therapeutics Assessment 23 Continued….
List of Figures
Number of Products under Development for Retinal Vein Occlusion, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Early Stage Products, H2 2016 12
Assessment by Monotherapy Products, H2 2016 23
Number of Products by Top 10 Targets, H2 2016 25
Number of Products by Stage and Top 10 Targets, H2 2016 25
Number of Products by Top 10 Mechanism of Actions, H2 2016 27
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 27
Number of Products by Routes of Administration, H2 2016 29
Number of Products by Stage and Routes of Administration, H2 2016 29
Number of Products by Molecule Types, H2 2016 31
Number of Products by Stage and Molecule Types, H2 2016 31
For more information or any query mail at email@example.com
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
WISE GUY RESEARCH CONSULTANTS PVT LTD
75 Arlington Street, Suite 500,
Boston, Massaachusetts – 02116
United States of America
+1 646 845 9349 / +44 208 133 9349